Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT06176027 | Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 52 | Navy General Hospital, BeijingOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT05772455 | A Study of XZB-0004 in Patients With Solid Tumors | recruiting | Phase 1 | 128 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT05156060 | Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer | recruiting | Phase 1 / Phase 2 | 64 | Natalie LockneyOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05312801 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma | recruiting | Phase 1 | 20 | Luminary TherapeuticsINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05546723 | LMY-920 for Treatment of Relapsed or Refractory Myeloma(LMY-920-002) | recruiting | Phase 1 | 30 | Luminary TherapeuticsINDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | recruiting | Phase 1 / Phase 2 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04275518 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | recruiting | Phase 1 | 102 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05299424 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 48 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06538012 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06635330 | Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | recruiting | Phase 1 / Phase 2 | 5 | Kara Yakhteh Tajhiz Azma CompanyNETWORK | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06611150 | Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma | recruiting | Phase 1 | 24 | Sun Yat-sen UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06617000 | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | recruiting | Phase 1 | 38 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614686 | U87 CAR-T in Patients With Advanced Head and Neck Tumors | recruiting | Phase 1 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06615193 | A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor | recruiting | Phase 1 | 111 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06079112 | 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 100 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06527898 | Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06589609 | Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer | recruiting | Phase 1 | 12 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592170 | Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)(MZL-001) | recruiting | Phase 1 / Phase 2 | 35 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593145 | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms(CARLA) | recruiting | Phase 1 | 6 | FamiCordTxINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585345 | Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia | recruiting | Phase 1 / Phase 2 | 200 | The General Hospital of Western Theater CommandOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06047197 | Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 25 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06572319 | Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens | recruiting | Phase 1 / Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06572514 | De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC | recruiting | Phase 1 / Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06343038 | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study(PROGNOSTICS) | recruiting | Phase 1 | 25 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06550713 | A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies | recruiting | Phase 1 | 100 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06452160 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 103 | BridGene Biosciences Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06271252 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | recruiting | Phase 1 | 81 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06517004 | An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | recruiting | Phase 1 | 32 | Ruijin HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04952272 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | recruiting | Phase 1 | 50 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03198546 | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03778814 | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05779917 | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05532696 | Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | recruiting | Phase 1 / Phase 2 | 61 | Anbogen Therapeutics, Inc.INDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06470256 | Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Zhiyong HuangOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06110572 | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation(TESSERACT) | recruiting | Phase 1 / Phase 2 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT03832127 | Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients(Myelofludate) | recruiting | Phase 1 | 35 | Nantes University HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06456892 | Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen | recruiting | Phase 1 / Phase 2 | 82 | Sun Yat-sen UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06445803 | CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL | recruiting | Phase 1 | 48 | Rong TaoOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06109558 | The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC(PROFILE) | recruiting | Phase 1 / Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | recruiting | Phase 1 | 28 | Osel, Inc.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 29, 2024source: clinicaltrials